Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
13,800
Employees13,800
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
13,800
Employees13,800

ZTS Key Statistics

Market cap
53.78B
Market cap53.78B
Price-Earnings ratio
20.57
Price-Earnings ratio20.57
Dividend yield
1.64%
Dividend yield1.64%
Average volume
4.94M
Average volume4.94M
High today
$122.36
High today$122.36
Low today
$116.00
Low today$116.00
Open price
$116.78
Open price$116.78
Volume
6.37M
Volume6.37M
52 Week high
$181.85
52 Week high$181.85
52 Week low
$115.25
52 Week low$115.25

Stock Snapshot

As of today, Zoetis(ZTS) shares are valued at $122.06. The company's market cap stands at 53.78B, with a P/E ratio of 20.57 and a dividend yield of 1.6%.

During the trading session on 2025-11-23, Zoetis(ZTS) shares reached a daily high of $122.36 and a low of $116.00. At a current price of $122.06, the stock is +5.2% higher than the low and still -0.2% under the high.

Trading volume for Zoetis(ZTS) stock has reached 6.37M, versus its average volume of 4.94M.

Over the past 52 weeks, Zoetis(ZTS) stock has traded between a high of $181.85 and a low of $115.25.

Over the past 52 weeks, Zoetis(ZTS) stock has traded between a high of $181.85 and a low of $115.25.

ZTS News

Benzinga 2d
Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst

As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovatio...

Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst
TipRanks 3d
KeyBanc starts Zoetis at Sector Weight on product launch headwinds, competition

KeyBanc analyst Steve Dechert initiated coverage of Zoetis (ZTS) with a Sector Weight rating. The firm is citing continued headwinds from the launch of the comp...

TipRanks 3d
Zoetis initiated with a Sector Weight at KeyBanc

KeyBanc initiated coverage of Zoetis (ZTS) with a Sector Weight rating. Published first on TheFly – the ultimate source for real-time, market-moving breaking f...

Analyst ratings

71%

of 21 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

More ZTS News

TipRanks 6d
Zoetis price target lowered to $130 from $140 at Stifel

Stifel analyst Jonathan Block lowered the firm’s price target on Zoetis (ZTS) to $130 from $140 and keeps a Hold rating on the shares. Following Q3 results, the...

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.